Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Clinical Oncology

• Publication date

  2013-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2013.31.15_SUPPL.3621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Bypassing the guardian: regulated cell death pathways in p53-mutant cancers

  2025cites this paper
• Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment.

  2024cites this paper
• Combination of bazedoxifene with chemotherapy and SMAC-mimetics for the treatment of colorectal cancer

  2024cites this paper
• Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours

  2024cites this paper
• The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

  2023cites this paper
• Targeting tumor resistance mechanisms

  2021cites this paper
• Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance.

  2020cites this paper
• The multiple roles of the IAP super-family in cancer.

  2020cites this paper
• Future Therapeutic Directions for Smac-Mimetics

  2020cites this paper
• SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases

  2020cites this paper
• An Updated Review of Smac Mimetics, LCL161, Birinapant, and GDC-0152 in Cancer Treatment

  2020cites this paper
• PEG-derivatized birinapant as a nanomicellar carrier of paclitaxel delivery for cancer therapy.

  2019cites this paper
• Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711

  2018cites this paper
• Synthesis and anticancer activity of conformationally constrained Smac mimetics containing pseudo β turns

  2018cites this paper
• Les inhibiteurs de l'apoptose, une nouvelle cible thérapeutique dans les glioblastomes

  2017cites this paper
• Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins

  2017cites this paper
• NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP

  2017cites this paper
• Inhibitors of apoptosis: clinical implications in cancer

  2017cites this paper
• SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.

  2016cites this paper
• Preclinical evaluation of apoptosis resensitisation with Inhibitor-of-apoptosis-protein (IAP) antagonist in glioblastoma cell lines and in an orthotopic mouse GBM model

  2016cites this paper
• A dual role for Caspase8 and NF-κB interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival

  2015cites this paper
• Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy

  2015cites this paper
• Promises and Challenges of Smac Mimetics as Cancer Therapeutics

  2015influential citation
• Small molecule inhibitor of apoptosis proteins antagonists: a patent review

  2015cites this paper
• Small-molecule SMAC mimetics as new cancer therapeutics.

  2014cites this paper
• Targeting apoptosis pathways for new cancer therapeutics.

  2014cites this paper
• A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.

  2014cites this paper